You have full text access to this OnlineOpen article

Vulvovaginal candidiasis in a Flemish patient population

  1. M. M. De Vos1,
  2. M. Cuenca-Estrella2,
  3. T. Boekhout3,4,
  4. B. Theelen3,
  5. N. Matthijs1,
  6. T. Bauters1,
  7. H. Nailis1,
  8. M. A. Dhont5,
  9. J. L. Rodriguez-Tudela2,
  10. H. J. Nelis1

Article first published online: 11 OCT 2005

DOI: 10.1111/j.1469-0691.2005.01281.x

Issue

Clinical Microbiology and Infection

Clinical Microbiology and Infection

Volume 11, Issue 12, pages 1005–1011, December 2005

Additional Information

How to Cite

De Vos, M. M., Cuenca-Estrella, M., Boekhout, T., Theelen, B., Matthijs, N., Bauters, T., Nailis, H., Dhont, M. A., Rodriguez-Tudela, J. L. and Nelis, H. J. (2005), Vulvovaginal candidiasis in a Flemish patient population. Clinical Microbiology and Infection, 11: 1005–1011. doi: 10.1111/j.1469-0691.2005.01281.x

Author Information

  1. 1

    Laboratory for Pharmaceutical Microbiology, Ghent University, Ghent, Belgium

  2. 2

    Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain

  3. 3

    Centraal bureau voor Schimmelcultures

  4. 4

    Department of Medicine, Division of Acute Medicine and Infectious Diseases, University Medical Centre, Utrecht, The Netherlands

  5. 5

    Department of Obstetrics and Gynaecology, Ghent University Hospital, Ghent, Belgium

*Corresponding author and reprint requests: H. J. Nelis, Harelbekestraat 72, 9000 Gent, Belgium E-mail: Hans.Nelis@UGent.be

Publication History

  1. Issue published online: 11 OCT 2005
  2. Article first published online: 11 OCT 2005
  3. Original Submission: 18 February 2005; Revised Submission: 26 April 2005; Accepted: 8 June 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (84K)

Keywords:

  • Antifungal agents;
  • Candida;
  • fluconazole;
  • susceptibility;
  • vaginitis;
  • vulvovaginal candidiasis

Abstract

Increased resistance to fluconazole has been reported in oral, oesophageal and urinary Candida isolates, but this has not been observed commonly in genital tract isolates. The rate of isolation of Candida spp. and their susceptibility to amphotericin B, flucytosine and azoles were determined in a number of clinical practices in the city of Ghent, Belgium. Patients with symptomatic vulvovaginal candidiasis (VVC) were treated with fluconazole, and the mycological and clinical outcomes were evaluated. Isolates were identified as Candida albicans (78.6%), Candida guilliermondii (17.3%), Candida glabrata (2.6%) and Candida dubliniensis (1.3%). The rates of mycological and clinical cures were 79.5% and 100%, respectively. Women with recurrent VVC were infected more frequently by non-albicans Candida spp., but no association was found between the use of antifungal agents and the presence of non-albicans spp. In-vitro resistance to fluconazole was not detected, even among subsequent Candida isolates from nine patients for whom mycological cure was not achieved.

View Full Article (HTML) Get PDF (84K)